Trial Profile
Treatment of COVID-19 With Opaganib in Patients With Pneumonia Requiring Oxygen But Not Mechanical Ventilation
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I/II
Latest Information Update: 27 Aug 2020
Price :
$35
*
At a glance
- Drugs Opaganib (Primary)
- Indications COVID 2019 infections; Pneumonia
- Focus Adverse reactions; Therapeutic Use
- Acronyms Opaganib-RHB
- Sponsors RedHill Biopharma
- 04 Aug 2020 Status changed from planning to not yet recruiting.
- 27 Jul 2020 New trial record
- 16 Jul 2020 According to a RedHill Biopharma media release, company has received approval from the Israeli Ministry of Health to initiate this study.